Objectives: Nebulized colistimethate sodium (CMS) can be used to treat ventilator-associated pneumonia caused by MDR bacteria. The influence of the diluent volume of CMS on aerosol delivery has never been studied. The main objectives of the study were to compare aerosol particle characteristics and plasma and urine pharmacokinetics between two diluent volumes in patients treated with nebulized CMS.
Introduction
Colistimethate sodium (CMS) is an inactive pro-drug of colistin (active metabolite) that forms colistin by spontaneous hydrolysis in aqueous solution. Colistin is a complex, multicomponent antibiotic mixture, 1 with colistin A and colistin B accounting for $85% of this mixture. [2] [3] [4] [5] The antibiotic effect of colistin A and B is concentration dependent. 1 Bergen et al. 1, 6 additionally described a high correlation between the overall killing effect of Pseudomonas aeruginosa and the ratio of the area under the concentration-time curve (AUC) of plasma concentrations of unbound colistin over MIC.
According to experimental models, nebulization of CMS offers the possibility of generating high colistin concentrations at the site of infection. 7 In addition, nebulized CMS is often used to treat ventilator-associated pneumonia (VAP) caused by MDR Gramnegative bacteria. [8] [9] [10] [11] [12] [13] The reported regimens for nebulized CMS range between 6 and 15 million international units (MIU) administered two or three times daily, and pharmacokinetic and clinical studies suggest that high doses of nebulized CMS compensate for colistin loss due to extrapulmonary deposition. [12] [13] [14] [15] [16] The 'summary of product characteristics' recommends dissolving each 1 MIU of CMS with 3 mL of normal saline solution. 17 As a result, 12 mL of saline is required when a high dose of 4 MIU is nebulized. Using high dilutions has, however, two disadvantages. First, it can increase nebulization time, 18 compromising antibiotic stability and clinical tolerance. 19 Second, as the volumes of the nebulizer chambers generally used for nebulization of antibiotics are often ,10 mL, the nebulizer chamber needs to be filled at least twice to nebulize 12 mL of CMS. This not only increases nurses' workload, but also carries the risk of incomplete administration. Decreasing the volume of diluent for the same dose of drug could have the advantage of reducing preparation and delivery time; however, the increased viscosity could change the properties of the aerosol. The impact of CMS concentration on the efficiency of aerosol delivery has never been studied.
The aim of this study was to compare aerosol characteristics and pharmacokinetics between two dilutions of CMS in patients with VAP due to MDR Gram-negative bacteria treated with nebulized CMS. To this purpose, we conducted a bench study to determine the CMS particle size and a clinical study to assess the plasma pharmacokinetics and urinary elimination of CMS and colistin following administration of nebulized CMS.
Methods
From April 2015 to July 2016, a particle size study of the aerosols produced by nebulizers was performed in the laboratory of the Service des Explorations Fonctionnelles de la Respiration, de l'Exercice et de la Dyspnée and a prospective and crossover clinical study was conducted in the multidisciplinary ICU. Concentrations of colistin and CMS were measured in the pharmacology department of La Pitié-Salpêtrière Hospital. In both studies, 6 mL (experimental dilution) and 12 mL (recommended dilution) diluent volumes for 4 MIU of CMS were compared; a vibratingmesh nebulizer with a maximum fill volume of 6 mL was used for nebulization (Aeroneb V R Solo, Galway, Ireland). The study protocol was approved by the Comité de Protection des Personnes (CPP-Ile-de-France VI) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent was obtained from the patients and/or patients' relatives.
Bench study for determination of particle sizes
The nebulizer chamber was loaded with 4 MIU of CMS dry powder for nebulization (Colimycin, Sanofi-Aventis, France), diluted in 6 or 12 mL of normal saline solution. The nebulizer was connected to the inspiratory limb of the ventilator circuit, 15 cm away from the Y-piece. During nebulization, the following ventilator settings were used: volume-controlled mode with constant inspiratory flow, respiratory rate of 12 breaths/min, inspiratory/ expiratory (I/E) ratio of 50% and end-inspiratory pause representing 20% of the duty cycle.
Aerosol particle size was determined using a laser aerosol particle sizer based on light diffraction with a measurement range between 0.3 and 10 lm over 16 channels (Topas Gmbh V R , Dresden, Germany). Direct sampling of the aerosol was done under a suction hood (temperature C, humidity 39%-46%) at the tip of the endotracheal tube (inner diameter 7.5 mm; Covidien, Ireland) with a sampling flow rate of 3 L/min. Analysis of the aerosol during 10 s runs provided the particle size spectrum and allowed the calculation of the mass median aerodynamic diameter (MMAD or D50) and of the diameter below which 90% of the aerosolized particle sizes are included (D90). This analysis was repeated every 15 min until the nebulizer chamber emptied (a total of 12 measurements per hour) and each dilution was studied three times.
The primary endpoint was the aerosol particle size (D50 and D90) produced during nebulization and the second endpoint was the aerosol particle size produced at the start and end time of nebulization.
Pharmacokinetic study in patients with VAP
The criteria for eligibility were age .18 years and a VAP due to MDR Gram-negative bacteria requiring treatment with nebulized CMS. 20 Patients with renal failure requiring renal replacement and patients treated with a combination of nebulized and intravenous CMS were excluded from the study. Creatinine clearance (CL CR ) was estimated by measuring the 24 h urine/plasma creatinine ratio.
All patients were treated with 4 MIU of CMS nebulized every 8 h (corresponding to 320 mg of CMS). At inclusion, the eight patients were randomized into two fixed blocks of four, one block comprising the 6 mL dilution arm (study started with 6 mL) and the other the 12 mL dilution arm (study started with 12 mL). The solutions of 4 MUI of CMS dissolved in 6 or 12 mL of normal saline were nebulized using a vibrating-mesh nebulizer according to a random order. The CMS solutions were prepared immediately before administration. The nebulizer was connected to the inspiratory limb of a non-humidified ventilator circuit, 15 cm from the Y-piece. During nebulization, mechanical ventilation was performed using a volume-controlled mode with a constant flow, an I/E ratio of 0.5, a respiratory frequency between 14 and 18 breaths/min and a tidal volume of 6-8 mL/kg. A strict coordination between patient and ventilator was required and therefore 2 mg/kg propofol was infused to mitigate patient-ventilator asynchrony.
The study protocol is shown in Figure 1 . For each dilution, sampling was performed after a minimum of two consecutive days of administration of nebulized CMS with the same dilution. Thereafter, the treatment was switched to the second dilution. Five successive plasma and urine samples were drawn immediately before the administration of CMS and 2, 4, 6 and 8 h after starting nebulization of CMS. All blood samples were collected in tubes containing lithium heparin, and plasma was separated immediately into 5 mL polypropylene vials. Urine samples were collected directly from the proximal part of the bladder catheter every 2 h and urine volume was measured at the time of each urine collection. Plasma and urine samples were immediately stored at -80 C until analysis within a maximum period of 2 months. 21 The primary endpoint was the plasma AUC from 0 to 8 h (AUC 0-8 ) of colistin A, colistin B, and the sum of colistin A and B (colistin A!B ).
The secondary endpoints were based on the following parameters:
• Plasma AUC 0-8 of CMS A and CMS B and the sum of CMS A and B (CMS A!B ).
• Renal clearance (CL R ) of colistin A, colistin B, CMS A and CMS B.
• Urinary elimination of colistin A!B and CMS A!B from 0 to 8 h (Qu 0-8 ).
• Nebulization time.
• Correlations between plasma trough concentration (C 0 ) of colistin A!B or CMS A!B and CL CR , and between plasma AUC 0-8 of colistin A!B or CMS A!B and CL CR measured on the same day.
• Stability of colistin A and colistin B in normal saline solution.
Samples were analysed for colistin A and B by UPLC-MS/MS using a method developed by Bihan et al. 12 The method proved to be accurate and precise in the range from 30 to 6000 ng/mL for colistin A and from 15 to 3000 ng/mL for colistin B; the within-day precision (CV %) was lower than 15%. The limit of quantification was 60 ng/mL for colistin A and 30 ng/mL for colistin B.
12
The plasma pharmacokinetics of colistin and CMS were evaluated from the concentration-time data at each dilution by a non-compartmental analysis using WinNonlin pharmacokinetic software, version 5.2 (Pharsight Corporation V R , Mountain View, CA, USA). Graphical analysis and determination of AUC 0-8 were performed using a linear trapezoidal model.
Colistin and CMS CL R was estimated using the following formula:
where U and P are the urine and plasma antibiotic concentrations and V is the 2 h urine volume. The total amount of colistin and CMS eliminated in Bihan et al.
the urine (Qu 0-8 ) between two nebulizations was estimated by adding the amount eliminated every 2 h. CMS concentrations were calculated indirectly from the difference between colistin concentrations determined after acidic treatment and unhydrolysed colistin concentrations directly determined without acidic treatment as previously described. 12, 22, 23 The stability of colistin A or B was assessed in triplicate at two dilutions: 1 MIU of CMS in 1.5 mL of normal saline (representing 4 MUI/6 mL) and in 3.0 mL of normal saline (representing 4 MUI/12 mL). Each sample was kept at room temperature for 9 h and analysed at 1, 2, 4, 6 and 9 h after reconstitution. Both molecules were considered stable in normal saline when measured signal intensities were within the limits of 95%-105% of the initial signal intensity.
Statistical analysis
Statistical analysis was performed using Sigmastat, version 3.5 (SystatS V R , USA) software. Quantitative variables are presented as mean + SD for the bench study and median (IQR) for the clinical study. Particle sizes produced with 6 and 12 mL diluent volumes were compared using bilateral unpaired Student's t-test. Two-way analysis of variance for repeated measures was used to compare changes in particle sizes (D50 and D90) over time using 6 and 12 mL diluent volumes; these parameters were log-transformed. Differences in pharmacokinetic parameters in patients between 6 and 12 mL diluent volumes were evaluated with the Wilcoxon signed-rank test. Correlations between CL CR and C 0 or AUC 0-8 of colistin A!B or CMS A!B were analysed using the Spearman correlation. A P value of ,0.05 was considered statistically significant.
Results

Aerosol particle sizes
Overall, D50 (MMAD) was bigger with 6 mL than with 12 mL of diluent volume (1.4+0.2 versus 0.9+0.2 lm, P , 0.001). At the end of nebulization, 90% of aerosolized particles had a diameter of ,3.0+0.6 lm when using a diluent volume of 6 mL. As shown in Figure 2 , with a diluent volume of 12 mL, D50 and D90 increased significantly from the beginning to the end of nebulization compared with when a diluent volume of 6 mL was used. The particle sizes were not different between the two diluent volumes at the end of nebulization for D90 (P " 0.741). The nebulization time was significantly shorter with the 6 mL dilution (63+3 versus 90+15 min, P " 0.04).
Colistin and CMS pharmacokinetics
Eight patients who fulfilled the inclusion criteria were included: four in each arm of crossover CMS dilution. The clinical characteristics of the patients are summarized in Table 1 . CL CR values did not differ between the two conditions studied (P " 0.461). The duration of invasive mechanical ventilation before inclusion was 19 (8-27) days. VAP was caused by P. aeruginosa in seven patients and by Acinetobacter baumannii in one patient. The duration of treatment was 9 (8-11) days; the clinical cure rate was 63% and the ICU mortality was 13%.
As shown in Figure 3 , significant inter-individual variability was observed in plasma concentrations of colistin A!B and CMS A!B . However, as shown in Tables 2 and 3 , the plasma AUC 0-8 for colistin A!B and CMS A!B , the CL R of colistin A and B and CMS A and B, and the amount of colistin A!B and CMS A!B eliminated in the urine between 0 and 8 h did not differ between patients treated with either 6 or 12 mL diluent volumes. The total amount of colistin and CMS eliminated in the urine represented, respectively, 17% and 13% of the CMS initially placed in the nebulizer chamber for the 6 Screening 1st PK study 2nd PK study
Start of CMS nebulization Randomization
End of the study 6 mL arm 12 mL arm D9±2 D7±2 Switch D5±2 D2±2 D1±1 D0 Figure 1 . Clinical study protocol. PK " pharmacokinetic. Five successive vertical bars " PK study period of urine and plasma sampling at 0, 2, 4, 6 and 8 h after the beginning of CMS nebulization. D " day. Screening day " first day of CMS nebulization. Randomization day " patient randomized to either the 6 mL arm (group of patients starting CMS nebulization with 6 mL diluent volume) or the 12 mL arm (group of patients starting CMS nebulization with 12 mL diluent volume).
Diluent volume of colistimethate sodium for nebulization JAC and 12 mL diluent volumes (P " 0.4). There were no correlations between CL CR and Qu 0-8 for colistin and CMS.
The plasma C 0 of colistin A!B and the C 0 of CMS A!B were similar for the two diluent volumes (P " 0.844 and P " 0.383, respectively). Significant negative correlations were found between the C 0 of colistin A!B and CL CR (q " #0.713, P " 0.002) and between the plasma AUC 0-8 of colistin A!B and CL CR (q " #0.663, P " 0.005), but there was no correlation between the C 0 or plasma AUC 0-8 of CMS A!B and CL CR .
Nebulization time and stability of colistin A and B
The nebulization time in patients was significantly shorter with the 6 mL dilution compared with the 12 mL dilution [66 (58-75) versus 93 (69-136) min, P " 0.042].
As shown in Figure 4 , for colistin A, signal losses of 7.2%+6.9% and 34.9%+0.6% were observed 1 h after reconstitution of CMS with 6 and 12 mL, and 10.6%+7.4% and 40.5%+2.9% after 2 h, respectively. For colistin B, signal losses of 20.8%+6.0% and 37.5%+8.6% were observed 1 h after reconstitution with 6 and 12 mL, and 27.0%+2.1% and 42.7%+5.3% after 2 h, respectively. Colistin A and B signal losses at room temperature were greater when CMS was diluted in 12 mL. Less than 40% of the initial signal was detected for colistin A and colistin B after 9 h for both diluent volumes.
Discussion
The results of this study showed that 4 MIU of CMS diluted in 6 mL of normal saline generated MMADs of ,3 lm, which is Changes in particles sizes of CMS and colistin from the start to the end of one nebulization. The changes in particle sizes over time were analysed using a two-way ANOVA for repeated measures with two factors: effect of diluent volume (6 versus 12 mL) and effect of time (start versus end time of nebulization). The presence of an interaction (P , 0.05) between the two factors indicates a significant increase in particle sizes from the start to the end of nebulization with a diluent volume of 12 mL compared with a diluent volume of 6 mL. Open circles " 12 mL diluent volume. Filled circles " 6 mL diluent volume. T0 " start time of nebulization. T60 " end time of nebulization for 6 mL diluent volume. T75-90 " end time of nebulization for 12 mL diluent volume. Diluent volume of colistimethate sodium for nebulization
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Aerosol particle size is one of the most important variables for optimizing the dose deposited in the lung. Particles .5 lm have a strong tendency to deposit in the ventilator circuit and large airways, 24 and the optimal MMAD for distal lung deposition ranges between 0.5 and 3 lm. 25 An MMAD of 1.4 lm and 90% of particles ,3.0 lm indicate that the dilution of 4 MIU in 6 mL is suitable for distal lung deposition. Another finding supporting the use of this dilution is the stability of particle size during the nebulization period compared with the 12 mL diluent volume. The main limitation of this clinical study is the lack of any analysis of the lung epithelial lining fluid (ELF) to assess how much drug was actually delivered to the distal lung fields. Because of the clinical difficulties involved in sampling ELF in patients every 2 h, we designed the present study to evaluate the differences in the plasma pharmacokinetic parameters of colistin A!B and CMS A!B between the two dilutions. Following CMS nebulization, some of the converted colistin deposited on the distal lung diffuses through the alveolar-epithelium to reach the pulmonary interstitium where colistin exerts its bactericidal activity by binding to bacterial cell membranes. It is known that plasma concentrations of colistin and CMS at the steady state following CMS nebulization are significantly lower than, but correlated to, the lung ELF concentrations. 15, 16, 26 The crossover study made it possible to compare two diluent volumes because it eliminated most of the factors that influence plasma concentrations, such as ventilator settings, lung and kidney function, and inter-subject variability. Indeed, the pharmacokinetic analysis was performed with fewer time points. However, the observation that the plasma concentrations were stable over time and did not exhibit significant peaks suggests a regular diffusion of CMS and colistin through the alveolar-capillary barrier. The lack of any difference in the plasma AUC 0-8 between the two diluent volumes suggests strongly that nebulization with 6 mL is as efficient as with 12 mL in terms of colistin lung parenchyma deposition. In agreement with previous studies, high interindividual variability of plasma CMS and colistin concentrations was observed. 14, 15 The elimination pathways of colistin are for the most part unknown. 27 One explanation for this variability could be the conversion speed of CMS to colistin in plasma, which depends on renal elimination efficiency, as we found a negative correlation between CL CR and colistin plasma concentrations. It is difficult to compare our pharmacokinetic data with previously published studies in which different methodologies, doses and dilutions were used. 14, 15 In order to maintain the stability of colistin, the urine sample was taken by directly puncturing the proximal part of the bladder catheter. 22 It has been reported that 50% of the CMS dose intravenously administered is recovered in the urine within 24 h. 28, 29 In our study, 13%-17% of the CMS dose initially placed in the nebulizer chamber was recovered in the urine. The similar urinary elimination of CMS A!B and colistin A!B for each of the two dilutions used in this study supports the lack of any difference between the two diluent volumes in terms of lung deposition.
Our results confirmed a previous study showing that the stability of CMS and colistin is concentration dependent. 19 The instability of CMS solution over time at room temperature indicates that CMS solution should be reconstituted just before administration, and that the duration of nebulization should be limited as much as possible. Furthermore, colistin degradation products can cause pulmonary inflammatory reactions in animals, and may also contribute to human lung injury and induce bronchial hyper-reactivity. 30 Therefore, the lower dilution volume may also be advantageous from a safety standpoint. 31 The degradation products of colistin over time have not, however, been clearly identified. 16, 19 A vibrating-mesh nebulizer has been used to assess nebulized antibiotics in most experimental and clinical studies. 7, [11] [12] [13] 15 This device has certain advantages compared with a jet nebulizer in terms of reduced residual volume and increased amount of aerosol delivery. 32 A recent bench study using a vibrating-mesh nebulizer failed to find any difference in bronchodilator lung dose among different dilutions. 33 Although the optimal dosing of nebulized CMS in terms of efficacy and toxicity needs to be defined by further clinical trials, 15, 34 the current clinical use of nebulized CMS for treating pneumonia tends to administer high doses to overcome extrapulmonary loss and optimize colistin lung deposition. 11, 13 For a vibrating-mesh nebulizer with a maximum fill volume of 6 mL, the use of a 6 mL diluent volume reduces nursing workload and nebulization time while increasing colistin stability. As a consequence, it could improve treatment efficiency and potentially reduce side effects. 26, 35, 36 Our study is in line with recent expert opinion that strongly suggests focusing clinical investigations on achieving continuous improvements in nebulization techniques before implementing large clinical Phase III trials. 26, 34, 37 It should be pointed out that the results obtained in our study cannot be generalized to drug delivery by jet or ultrasonic nebulizers. Jet nebulizers tend to have high residual volumes of drug remaining in the chamber at the end of nebulization. Hence, using an increased fill volume of a more dilute solution could decrease the amount of drug trapped in the dead volume and thereby increase the aerosol delivery. 18 In conclusion, using a vibrating-mesh nebulizer for CMS delivery results in shorter nebulization time and better colistin stability with 4 MUI CMS in 6 mL normal saline. CMS and colistin pharmacokinetics are not influenced by reducing dilution. The aerosol particle size increases with the more concentrated solution, but the range remains in limits that do not impair distal lung deposition. These findings may contribute to improving clinical practice and optimizing the technique for CMS nebulization during clinical trials.
